Cover Image
市場調查報告書

血紅素加氧酶1:開發中產品分析

Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 368706
出版日期 內容資訊 英文 28 Pages
訂單完成後即時交付
價格
Back to Top
血紅素加氧酶1:開發中產品分析 Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) - Pipeline Review, H2 2016
出版日期: 2016年07月30日 內容資訊: 英文 28 Pages
簡介

本報告提供以血紅素加氧酶1為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

血紅素加氧酶1 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各分子類型

治療藥的開發企業

  • Selvita S.A.
  • 武田藥品工業

藥物簡介

暫停中的計劃

附錄

圖表

目錄
Product Code: GMDHC0421TDB

Summary

Global Markets Direct's, 'Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) - Pipeline Review, H2 2016', provides in depth analysis on Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) targeted pipeline therapeutics.

The report provides comprehensive information on the Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18)
  • The report reviews Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) Overview
  • Therapeutics Development
    • Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) - Products under Development by Stage of Development
    • Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) - Products under Development by Therapy Area
    • Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) - Products under Development by Indication
  • Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) - Pipeline Products Glance
    • Early Stage Products
  • Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) - Products under Development by Companies
  • Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) - Products under Development by Universities/Institutes
  • Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Molecule Type
  • Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) - Companies Involved in Therapeutics Development
    • Selvita S.A.
    • Takeda Pharmaceutical Company Limited
  • Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) - Drug Profiles
    • BTZO-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HYCO-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SEL-303 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Activate HO-1 for Endothelial Dysfunction, Asthma and Osteoarthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate HO-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Heme Oxygenase 1 (HO1 or HMOX1 or EC 1.14.14.18) - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Selvita S.A., H2 2016
  • Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Dormant Projects, H2 2016
  • Dormant Projects (Contd..1), H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top